In a dramatic reversal of 2013 moratorium FDA allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are the first direct-to-consumer (DTC) tests authorized by the FDA that provide information on an individual’s genetic predisposition to certain medical diseases or conditions, which may help to make decisions … [Read more...] about The FDA granted market authorization of the Personal Genome Service GHR tests to 23andMe